Progress in targeted therapy for breast cancer

Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems.

• Publication year

  2018

• Venue

  Chronic Diseases and Translational Medicine

• Publication date

  2018-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cdtm.2018.04.002PMID 30276363PMCID 6160667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2018cited by this paper
• Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

  2018cited by this paper
• San Antonio Breast Cancer Symposium 2017.

  2018cited by this paper
• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

  2017cited by this paper
• CDK4/6 inhibition triggers anti-tumor immunity

  2017cited by this paper
• Feasible and efficient identification of neoantigens for personalized cancer immunotherapy in advanced refractory epithelial cancer patients.

  2017cited by this paper
• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

  2017cited by this paper
• Olaparib Increased Survival in Metastatic Breast Cancer.

  2017cited by this paper
• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2017cited by this paper
• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

  2017cited by this paper
• MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

  2017cited by this paper
• Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

  2017cited by this paper
• A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

  2017cited by this paper
• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

  2017cited by this paper
• years ’ follow-up of trastuzumab after adjuvant chemotherapy in HER 2-positive early breast cancer : fi nal analysis of the HERceptin Adjuvant ( HERA ) trial

  2017cited by this paper
• Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.

  2016cited by this paper
• Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

  2016cited by this paper
• Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

  2016cited by this paper
• Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

  2016cited by this paper
• Palbociclib and Letrozole in Advanced Breast Cancer.

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

  2016cited by this paper
• SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

  2015cited by this paper
• Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

  2014cited by this paper
• Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

  2014influential reference
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2

  2014cited by this paper
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

  2014cited by this paper
• Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

  2013cited by this paper
• Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

  2013cited by this paper
• CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

  2012cited by this paper
• The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2011cited by this paper
• Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

  2010cited by this paper
• San Antonio Breast Cancer Symposium.

  2009cited by this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cited by this paper
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

  2008cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

  1985cited by this paper

• Machine learning-guided identification of metastasis-associated miRNAs and their integration into a PFI-based cox risk score and nomogram

  2026cites this paper
• The Combination of Natural Products: A Promising Therapeutical Way for Management of Breast Cancers

  2025cites this paper
• Targeted Therapy for Breast Cancer Treatment

  2025cites this paper
• Combination Treatment of Docetaxel with Phytol or Thymol Additively Inhibits the Proliferation of Breast Cancer Cells and Downregulates the Expression of Cancer Stem Cell Markers

  2025cites this paper
• Identification and Analysis of Potential Breast Anticancer Agents in Pogostemon Cablin through Network Pharmacology

  2024cites this paper
• Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review.

  2024cites this paper
• Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.

  2024cites this paper
• The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset

  2024cites this paper
• Clove Essential Oil: Chemical Profile, Biological Activities, Encapsulation Strategies, and Food Applications

  2024cites this paper
• The Combined Impact of Curcumin: Piperine and Sorafenib on microRNAs and Different Pathways in Breast Cancer Cells

  2024cites this paper
• Activation of autophagy promotes the inhibitory effect of curcumin analog EF‐24 against MDA‐MB‐231 cancer cells

  2024cites this paper
• Correlation Between miR-497-5p Expression With Clinicopathological Characteristics and Prognosis in Patients With Breast Cancer

  2024cites this paper
• Preparation of pillar[5]arene functionalized silica gel hybrid material: investigation of biological (antimicrobial, antioxidant and anti-cancer) properties

  2024influential citation
• Biological Analysis of Factors Influencing the Acceleration of Menopause Age in Indonesian Women

  2024cites this paper
• Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.

  2024cites this paper
• Investigation of Molecular Mechanisms Involved in Sensitivity to the Anti-Cancer Activity of Costunolide in Breast Cancer Cells

  2023cites this paper
• Surfaceome Profiling Suggests Potential of Anti-MUC1×EGFR Bispecific Antibody for Breast Cancer Targeted Therapy

  2023cites this paper
• Tenofovir alone or combined with doxorubicin abrogates DMBA-induced mammary cell carcinoma: An insight into its modulatory impact on oxidative/Notch/apoptotic signaling.

  2023cites this paper
• Discovery of novel PARP-1 inhibitors using tandem in silico studies: integrated docking, e-pharmacophore, deep learning based de novo and molecular dynamics simulation approach

  2023cites this paper
• Best treatment options for occult breast cancer: A meta-analysis

  2023influential citation
• Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries

  2023cites this paper
• Clinical factors affecting the long-term survival of breast cancer patients

  2023cites this paper
• Development and Validation of a Dual-Language (English and Malay) Needs Assessment Tool for Breast Cancer (NeAT-BC)

  2023cites this paper
• A review of the latest research medications and information on the inflammatory, molecular, pathological, and targeted aspects of breast cancer

  2022cites this paper
• In vivo, in vitro and in silico anticancer investigation of fullerene C60 on DMBA induced breast cancer in rats.

  2022cites this paper
• Proteomic analysis of inhibitor of apoptosis protein-like protein-2 on breast cancer cell proliferation

  2022cites this paper
• Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases

  2022cites this paper
• Camouflaged liposomes by 11A4-nanobody for co-delivery of cisplatin and nitroxoline in breast cancer tumors: An in vitro/in vivo study

  2022cites this paper
• Cancer mRNA Vaccines as a Promising Approach for Treating Luminal A Breast Cancer

  2022cites this paper
• A Review on Computational Analysis of Big Data in Breast Cancer for Predicting Potential Biomarkers.

  2022cites this paper
• Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer.

  2022cites this paper
• Photobiomodulation therapy combined with radiotherapy in the treatment of triple-negative breast cancer-bearing mice.

  2021cites this paper
• Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer.

  2021cites this paper
• Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling

  2021cites this paper
• The impact of CBP expression in estrogen receptor-positive breast cancer

  2021cites this paper
• Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis

  2021cites this paper
• AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review

  2021cites this paper
• Bioactive Cationic Peptides as Potential Agents for Breast Cancer Treatment.

  2021cites this paper
• Introduction : the need for new therapeutic options for breast cancer

  2021cites this paper
• Impacting the Remedial Potential of Nano Delivery-Based Flavonoids for Breast Cancer Treatment

  2021cites this paper
• Bioactive cationic peptides as potential agents for breast cancer treatment

  2021cites this paper
• Cytotoxic effects of novel solvothermal synthesised Ag-doped PEGylated WO3 sheet-like nanocomposites on MCF-7 human breast cancer cells

  2020cites this paper
• Corosolic acid의 유방암세포 증식 및 전이에 미치는 영향

  2020cites this paper
• Alzheimer ’ s Disease , Breast , Prostate Cancer

  2020cites this paper
• Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer -

  2020cites this paper
• Proteomic Analysis of Inhibitor of Apoptosis Protein-like Protein-2 on MCF-7 Cell Growth

  2020cites this paper
• Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

  2020cites this paper
• Bioactivity of Syzygium aromaticum (L.) Merr. & L.M.Perry extracts as potential antimicrobial and anticancer agents

  2020cites this paper
• Breast cancer: An insight into its inflammatory, molecular, pathological and targeted facets with update on investigational drugs.

  2020cites this paper
• Alzheimer’s Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research

  2020cites this paper
• Effect of corosolic acid on apoptosis and angiogenesis in MDA-MB-231 human breast cancer cells

  2020influential citation
• Bioactive Compounds: Multi-Targeting Silver Bullets for Preventing and Treating Breast Cancer

  2019cites this paper
• MCF7 meme kanseri hücreleri üzerine Verbascum inulifolium’un antiproliferatif ve apoptoz indükleme aktivitelerinin değerlendirilmesi

  2019cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Analysis of status and countermeasures of cancer incidence and mortality in China

  2019cites this paper
• Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone

  2019cites this paper
• Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance

  2019cites this paper
• Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

  2019cites this paper
• Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin

  2019cites this paper
• The Antiangiogenic Effects of Tamoxifen might be Attributed to Receptor Binding Capacity of its Solvent Dimethylsulfoxide in Breast Cancer: A Molecular Docking Study

  2019cites this paper
• Down-regulation of NAMPT expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin

  2019cites this paper
• Preparation, characterization and evaluation of solid lipid nanoparticles and niosomes for ING4 gene delivery to MCF-7 cells

  2019cites this paper